Table 1.

The Future: Therapies for Childhood Pkd

Class (compound)	ADPKD	ARPKD	CLINICAL TRIALS or pre-clinical reference (www.clinicaltrials.gov)
VPV2R Antagonists (Tolvaptin)	++/−	+/−−	Phase II–III NCT01022424 (III) in progress NCT01280721 (III) in progress NCT01214421 (III) recruiting NCT01451827 (II) recruiting
Src Inhibitors (Bosutinib)	+++	+++	Phase II NCT01233869 (II) recruiting
mTOR Inhibitors	+/− −	+/− −	Phase I–II NCT00414440-in progress NCT00286156 NCT01009957 (II,III)-recruiting
Multi-Kinase Inhibitors (KD-019)	+++	++/?	Phase I–II NCT01559363 (I–II) recruiting
Somatostatins Long Acting analogues (Octreonide & Laneonide)	++/?	++/?	Phase III NCT01377246 (III) recruiting NCT01354405 (III) in progress
(Lisinopril and Telmisartan) HALT PKD	++/?	++/?	NCT00283686 (III) in progress
(Diterpene) (Triptolide Woldifii)	+/??	+/??	NCT00801268 (II) (China only)
EGFR-Axis Inhibitors	+++	+++	(40) (42)
Angiogenesis Inhibitors/MMP-inhibitors	++/?	++/?	(74)
SMAC Mimetics/ HDAC-i/TNF-α	++/?	++/?	(75) (76)
20-HETE	++/?	++/?	(77) (78)
ROS-i	++/?	++/?	(79)
Manipulation of Genetic Modifiers	++/?	++/?	(80)